Dual-Responsive DNA Nanodevice for the Available Imaging of an Apoptotic Signaling Pathway in Situ

ACS Nano ◽  
2019 ◽  
Vol 13 (11) ◽  
pp. 12840-12850 ◽  
Author(s):  
Hai Shi ◽  
Yanxia Wang ◽  
Ji Zheng ◽  
Limin Ning ◽  
Yue Huang ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Apoptotic Signaling ◽  
Dual Responsive

scholarly journals Tanshinone‑IIA inhibits myocardial infarct via decreasing of the mitochondrial apoptotic signaling pathway in myocardiocytes

2021 ◽  
Vol 48 (2) ◽  
Author(s):  
Yeqing Fang ◽  
Chengcheng Duan ◽  
Shaoyuan Chen ◽  
Zhenguo Liu ◽  
Bimei Jiang ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Myocardial Infarct ◽  
Tanshinone Iia ◽  
Apoptotic Signaling

scholarly journals Pravastatin slows the progression of heart failure by inhibiting the c-Jun N-terminal kinase-mediated intrinsic apoptotic signaling pathway

2013 ◽  
Vol 8 (4) ◽  
pp. 1163-1168 ◽  
Author(s):  
SHIPING CAO ◽  
ZHI ZENG ◽  
XIANBAO WANG ◽  
JIANPING BIN ◽  
DINGLI XU ◽  
...  
Keyword(s):  
Heart Failure ◽  
Signaling Pathway ◽  
Apoptotic Signaling

In situ biosynthesized gold nanoclusters inhibiting cancer development via the PI3K–AKT signaling pathway

2019 ◽  
Vol 7 (35) ◽  
pp. 5336-5344 ◽  
Author(s):  
Maonan Wang ◽  
Zeqian Yu ◽  
Huan Feng ◽  
Jianling Wang ◽  
Lishan Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Signaling Pathway ◽  
Gold Nanoclusters ◽  
Akt Signaling ◽  
Cancer Development ◽  
Akt Signaling Pathway

Nanomaterials have made great breakthroughs in drug delivery.

Can luteolin be a therapeutic molecule for both colon cancer and diabetes?

2018 ◽  
Vol 18 (4) ◽  
pp. 230-239 ◽  
Author(s):  
Rashmi K Ambasta ◽  
Rohan Gupta ◽  
Dhiraj Kumar ◽  
Saurabh Bhattacharya ◽  
Aditi Sarkar ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Signaling Pathway ◽  
World Health ◽  
Molecular Signaling ◽  
Immunofluorescence Analysis ◽  
Number Of Patients ◽  
Patients With Diabetes ◽  
Health Organization ◽  
Multiple Signaling

Abstract Diabetes and colon cancer are the leading cause of mortality worldwide. According to World Health Organization, the number of patients with diabetes and cancer is going to be elevated by 50% in 2020. However, several flavonoids have been known to be useful in reducing the chance of cancer/diabetes but the hunt of a single biomolecule that can act as therapeutic and preventive molecules for future epidemic continues. In this review, we aim to perform an illustration of all researches done that target molecular signaling using luteolin in cancer/diabetes and predicted target protein using PharmMapper. The search confirms that luteolin can be a remedial molecule for both cancer and diabetes via acting on variety of signaling pathway. Furthermore, we also intend to illustrate/compare the predicted and verified molecular modes of action of luteolin. Fluorescence in situ hybridization analysis confirms the expression of CCND1 in colon cancer while immunofluorescence analysis confirms the CDK4 in diabetes. Finally, an effort has been made to map docking of marker protein-luteolin at a particular site using docking software. This review gives a holistic overview about luteolin as a therapeutic molecule for cancer/diabetes via acting on multiple signaling cascade such as p53, Wnt, eNOS, iNOS, SOD and MMP9, with especial emphasis on the cyclin-CDK pathway. Altogether, the review concludes that luteolin can be a molecule for the therapy of both cancer and diabetes by acting on broad signaling pathway.

scholarly journals In situ evidence of collagen V and signaling pathway of found inflammatory zone 1 (FIZZ1) is associated with silicotic granuloma in lung mice

2020 ◽  
Vol 216 (9) ◽  
pp. 153094
Author(s):  
Vanessa Martins ◽  
Adriana Lopes da Silva ◽  
Walcy Rosolia Teodoro ◽  
Ana Paula Pereira Velosa ◽  
Marcelo Luiz Balancin ◽  
...  
Keyword(s):  
Signaling Pathway
Sign in / Sign up

Export Citation Format

Share Document